Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An examination of the investment activity ratios reveals distinct trends over the observed period. Generally, the ratios demonstrate relative stability with some notable shifts beginning in late 2023 and continuing into the forecast period. These shifts suggest potential changes in asset utilization and financial leverage.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio exhibited a gradual decline from 5.18 in the first quarter of 2022 to 4.88 in the third quarter of 2022. This was followed by a recovery, increasing to 5.28 by the fourth quarter of 2024. The ratio then experienced a slight decrease to 5.16 in the fourth quarter of 2025. This pattern indicates an initial decrease in the efficiency of fixed asset utilization, followed by improvement and stabilization at a higher level. The overall trend suggests increasing efficiency in generating revenue from fixed assets.
- Total Asset Turnover
- The total asset turnover ratio remained consistently around 0.43 for the first three quarters of 2022 and the first quarter of 2023. A noticeable increase began in the second quarter of 2023, reaching 0.52 in the second quarter of 2024. The ratio then decreased to 0.48 in the fourth quarter of 2024 and stabilized around 0.49 in 2025. This suggests an improvement in the company’s ability to generate sales from its total asset base, followed by a slight moderation. The increase indicates improved asset utilization efficiency.
- Equity Turnover
- The equity turnover ratio demonstrated a declining trend from 1.37 in the first quarter of 2022 to 1.18 in the fourth quarter of 2022. The ratio remained relatively stable through the first half of 2023. A significant increase occurred starting in the third quarter of 2023, peaking at 1.56 in the first quarter of 2024, before decreasing to 1.27 in the fourth quarter of 2025. This pattern suggests a period of decreasing revenue generation per dollar of equity, followed by a substantial improvement and subsequent stabilization at a lower, but still elevated, level. The initial decline may indicate a reliance on debt financing, while the later increase suggests improved profitability relative to equity.
In summary, the observed ratios indicate a period of initial stability followed by improvements in asset utilization and revenue generation relative to both total assets and equity. The fluctuations suggest dynamic shifts in operational efficiency and financial leverage strategies.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Property, plant and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio for the analyzed period demonstrates a generally stable performance with subtle fluctuations. Initially, the ratio exhibited a slight downward trend from 5.18 in the first quarter of 2022 to 4.88 in the third quarter of the same year. A modest recovery followed, reaching 5.07 by the end of 2022. This pattern of relative stability continued through 2023 and into 2024, with the ratio oscillating within a narrow range, peaking at 5.28 in the fourth quarter of 2024.
- Overall Trend
- The ratio generally remained above 5.0, indicating efficient utilization of fixed assets to generate sales. While there were quarterly variations, a clear, sustained upward or downward trend was not apparent throughout the observed period. The ratio appears to have plateaued in the 5.1 to 5.3 range in the latter half of the analysis.
- Short-Term Fluctuations
- A minor dip was observed in the third quarter of 2022, potentially attributable to seasonal factors or temporary inefficiencies in asset utilization. The subsequent increase in the fourth quarter of 2022 suggests a correction of these factors. Similar, smaller fluctuations occurred throughout 2023 and 2024, but these did not significantly alter the overall stable trend.
- Recent Performance
- The most recent quarters show a slight decrease from 5.28 in December 2024 to 5.16 in December 2025. This minor decline warrants monitoring to determine if it signals the beginning of a more pronounced downward trend or remains within the range of normal quarterly variation. The ratio remains healthy, but the slight decrease could indicate a need to evaluate asset utilization strategies.
In summary, the net fixed asset turnover ratio indicates consistent and effective asset management. The observed fluctuations are relatively minor and do not suggest any significant concerns regarding the company’s ability to generate sales from its fixed asset base. Continued monitoring of the ratio, particularly the recent slight decline, is recommended.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio remained relatively stable for the first eight quarters presented, before exhibiting some fluctuation. Throughout much of the period, the ratio hovered around 0.43 to 0.44. A noticeable upward trend began in the first quarter of 2024, continuing through the second quarter of that year, before stabilizing and then slightly declining in subsequent quarters.
- Overall Trend
- From March 31, 2022, to December 31, 2023, the total asset turnover ratio demonstrated minimal variation, consistently ranging between 0.43 and 0.44. This suggests a consistent level of efficiency in utilizing assets to generate sales during this period. However, beginning in March 2024, the ratio began to increase.
- Increase in 2024
- The ratio increased from 0.48 in March 2024 to 0.52 in June 2024, indicating improved asset utilization. This increase suggests that the company generated more sales revenue for each dollar of assets employed. The ratio remained at 0.52 in September 2024 before decreasing to 0.48 in December 2024.
- Recent Performance
- Following the peak in the second quarter of 2024, the total asset turnover ratio experienced a slight decline, settling at 0.49 in December 2025. While still above the levels observed prior to 2024, this suggests a potential moderation in the efficiency gains achieved earlier in the year. The ratio remained at 0.49 in the most recent quarter, June 30, 2025.
The observed fluctuations warrant further investigation to determine the underlying drivers. Changes in product sales, asset composition, or operational efficiency could all contribute to these shifts in the total asset turnover ratio.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Total Gilead stockholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Total Gilead stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates fluctuations, generally indicating a changing relationship between product sales and stockholders’ equity. An initial period of relative stability is followed by a notable shift, then a return towards earlier levels.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The equity turnover ratio begins at 1.37 and experiences a slight decline to 1.27 over the first nine months. It remains stable at 1.27 for the final quarter of 2022. This suggests a consistent, though modestly decreasing, efficiency in generating sales from the equity base during this timeframe.
- Transitional Phase (Mar 31, 2023 – Dec 31, 2023)
- The ratio remains relatively flat, fluctuating between 1.27 and 1.18. This indicates a period of stabilization, albeit at a slightly lower level than the beginning of the analyzed period. The slight downward trend may suggest a slower rate of sales generation relative to equity.
- Significant Increase (Mar 31, 2024 – Sep 30, 2024)
- A substantial increase is observed, with the ratio rising from 1.56 to 1.52. This suggests a significantly improved efficiency in utilizing equity to generate product sales. The increase is notable and warrants further investigation to understand the underlying drivers.
- Subsequent Moderation (Dec 31, 2024 – Dec 31, 2025)
- Following the peak, the equity turnover ratio experiences a gradual decline, moving from 1.48 to 1.27. While remaining above the levels seen in early 2023, this trend suggests a return towards more moderate levels of sales generation relative to equity. The final value of 1.27 is comparable to the ratio observed in late 2022.
Overall, the equity turnover ratio demonstrates a cyclical pattern. The initial stability gives way to a period of increased efficiency, followed by a moderation. These fluctuations likely reflect changes in sales volume, equity levels, or a combination of both. The increase in the ratio during the first half of 2024 is a key observation, potentially indicating successful strategic initiatives or market conditions.